-
Net Loss: $11.4 million for Q4 2024, compared to $7.8 million in Q4 2023.
-
R&D Expenses: $9.3 million in Q4 2024, up from $6.5 million in Q4 2023.
-
G&A Expenses: $2.9 million in Q4 2024, compared to $2.4 million in Q4 2023.
-
Cash, Cash Equivalents, and Marketable Securities: $107.6 million as of December 31, 2024.
-
Cash Burn Guidance: Expected $12 million to $14 million per quarter in Q1 and Q2 2025.
-
Fully Diluted Shares Outstanding: Approximately 137 million, including 10 million stock options.
Release Date: March 18, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
-
Trevi Therapeutics Inc (NASDAQ:TRVI) reported three positive data readouts in 2024, including the Human Abuse Potential study, the CORAL study in chronic cough patients with IPF, and the RIVER study in patients with refractory chronic cough.
-
The company successfully conducted trials across 11 countries and approximately 75 different sites, demonstrating strong execution and commitment to high-quality trials.
-
The Human Abuse Potential study showed statistically significant lower relative drug liking for nalbuphine doses compared to butorphanol, supporting its safety profile.
-
The Phase 2a RIVER trial met its primary endpoint with a statistically significant reduction in 24-hour objective cough frequency, showing promise for Haduvio in treating RCC.
-
Trevi Therapeutics Inc (NASDAQ:TRVI) has a strong cash position with $107.6 million in cash, cash equivalents, and marketable securities, providing a cash runway into the second half of 2026.
-
Trevi Therapeutics Inc (NASDAQ:TRVI) reported a net loss of $11.4 million for the fourth quarter of 2024, an increase from the $7.8 million loss in the same quarter of 2023.
-
Research and development expenses increased significantly to $9.3 million during the fourth quarter of 2024, primarily due to increased clinical trial costs.
-
General and administrative expenses also rose to $2.9 million during the fourth quarter of 2024, driven by increased stock-based compensation and personnel-related expenses.
-
The company faces uncertainty regarding the final determination of nalbuphine’s scheduling status, which will be made upon FDA and DEA approval.
-
Trevi Therapeutics Inc (NASDAQ:TRVI) needs to conduct further studies and regulatory discussions to advance Haduvio’s development, which may impact timelines and require additional resources.
Q: Could you speak about the patients enrolled in the CORAL study and any differences observed in the first and second halves of the study? A: Jennifer Good, President and CEO, explained that no changes were made to the study as it was already 75-80% enrolled by December. The study statistics remained consistent, and no changes were communicated to the sites to ensure consistency in the study protocol.
